GlaxoSmithKline reports return to profit in second quarter

July 26, 2011

British drugmaker GlaxoSmithKline posted net profit of more than £1.1 billion in the second quarter on Tuesday following a loss during the equivalent three-month period in 2010.

GSK said in a statement that earnings after tax stood at £1.106 billion (1.252 billion euros, $1.814 billion) in the quarter ending June 30 compared with a net loss of £304 million in the second quarter last year.

The company had fallen into a loss a year ago owing to exceptional legal charges linked to its former diabetes drug Avandia, which has been pulled from European shelves on fears that it increased the risk of heart attack and strokes.

"We have had a strong second quarter," GSK chief executive Andrew Witty said in the company's earnings statement.

"Going forward, we continue to apply sustained pressure to GSK's cost base to realise further savings, through improvements in areas such as support functions, supply chain and procurement efficiency."

GSK was rocked last September when the EU medicines regulator decided to pull Avandia off the shelves. Regulators also restricted its availability in the United States.

The EU decided to pull Avandia owing to concerns over its active substance rosiglitazone. It decided also to halt the sale of Glaxo's other diabetes drugs, Avandamet and Avaglim, since they too contained rosiglitazone.

Meanwhile sales of GSK's herpes treatment Valtrex have been hit by generic competition.

GSK added Tuesday that revenues declined by four percent to £6.72 billion in the second quarter.

Related Stories

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.